Arkolith/Insider Trading/JANX/Form 4

Campbell David Alan

President and CEO, DirectorJanux Therapeutics, Inc. (JANX) · full profile →Form 4 · filed Jul 11, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 8, 2026Option exercise(M)7K$4.21$29K389K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jul 8, 2026Option exercise(M)7K—$0698K

Transaction Codes

M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001864158-26-000004) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML